Esperion Therapeutics Inc. (ESPR) Given Average Recommendation of “Hold” by Analysts
Esperion Therapeutics Inc. (NASDAQ:ESPR) has been given an average rating of “Hold” by the fourteen analysts that are currently covering the firm. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $27.16.
Several equities research analysts have issued reports on the stock. Vetr raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 price target on the stock in a research note on Monday, August 8th. WallachBeth Capital cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a research note on Tuesday, July 5th. Citigroup Inc. reiterated a “buy” rating and set a $22.00 price objective (down from $36.00) on shares of Esperion Therapeutics in a report on Wednesday, June 29th. Lake Street Capital cut their price objective on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, June 29th. Finally, Chardan Capital reiterated a “neutral” rating and set a $12.50 price objective on shares of Esperion Therapeutics in a report on Saturday.
Esperion Therapeutics (NASDAQ:ESPR) traded down 0.65% during midday trading on Wednesday, hitting $12.30. 81,597 shares of the stock were exchanged. The stock’s market cap is $277.36 million. The firm has a 50 day moving average of $12.43 and a 200-day moving average of $13.85. Esperion Therapeutics has a 12-month low of $9.58 and a 12-month high of $30.41.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/esperion-therapeutics-inc-espr-given-average-recommendation-of-hold-by-analysts.html
Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same quarter last year, the firm earned ($0.55) EPS. On average, equities analysts expect that Esperion Therapeutics will post ($3.37) earnings per share for the current year.
Several hedge funds have recently bought and sold shares of the stock. Quantitative Investment Management LLC purchased a new stake in Esperion Therapeutics during the second quarter worth about $111,000. Advisor Group Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth about $140,000. Stifel Financial Corp raised its stake in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares in the last quarter. Rhumbline Advisers raised its stake in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares in the last quarter. Finally, ProShare Advisors LLC raised its stake in Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares in the last quarter. Institutional investors own 65.23% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.